Johnny A. Diaz

Johnny A. Diaz

Auto-generated profile, based on publicly available information

Johnny A. Diaz

University of California, Los Angeles 1 Molecular Biology Interdepartmental Program Los Angeles, California

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 December 2023 in Nature Cell Biology
Verified
Journal Article
Open access
PDF file
JGJenna M. Giafaglione
Jenna M. Giafaglione
PCPreston D. Crowell
Preston D. Crowell
ADAmelie M. L. Delcourt
Amelie M. L. Delcourt
THTakao Hashimoto
Takao Hashimoto
SHSung Min Ha
Sung Min Ha
AGAndrew S. Goldstein
Andrew S. Goldstein
Lineage transitions are a central feature of prostate development, tumourigenesis and treatment resistance. While epigenetic changes are well known to drive prostate lineage transitions, it remains unclear how upstream metabolic signalling contributes to the regulation of prostate epithelial identity. To fill this gap, we developed an approach to perform metabolomics on primary prostate epithelial cells. Using this approach, we discovered that the basal and luminal cells of the prostate exhibit distinct metabolomes and nutrient utilization patterns. Furthermore, basal-to-luminal differentiation is accompanied by increased pyruvate oxidation. We establish the mitochondrial pyruvate carrier and subsequent lactate accumulation as regulators of prostate luminal identity. Inhibition of the mitochondrial pyruvate carrier or supplementation with exogenous lactate results in large-scale chromatin remodelling, influencing both lineage-specific transcription factors and response to antiandrogen treatment. These results establish reciprocal regulation of metabolism and prostate epithelial lineage identity.

27 January 2026 in Molecular Cancer Research
Verified
Journal Article
Closed access
MBMatthew J. Bernard
Matthew J. Bernard
AGAndrea Gallardo
Andrea Gallardo
ARAngel Ruiz
Angel Ruiz
JDJohnny A. Diaz
Johnny A. Diaz
NNNicholas M. Nunley
Nicholas M. Nunley
AGAndrew S. Goldstein
Andrew S. Goldstein
As cancer cells evade therapeutic pressure and adopt alternate lineage identities not commonly observed in the tissue of origin, they likely adopt alternative metabolic programs to support their evolving demands. Targeting these alternative metabolic programs in distinct molecular subtypes of aggressive prostate cancer may lead to new therapeutic approaches to combat treatment resistance. We identify the poorly studied metabolic enzyme oxoglutarate dehydrogenase-like (OGDHL), named for its structural similarity to the tricarboxylic acid (TCA) cycle enzyme oxoglutarate dehydrogenase, as an unexpected regulator of tumor growth, treatment-induced lineage plasticity, and DNA damage in prostate cancer. Although OGDHL has been described as a tumor suppressor in various cancers, we find that its loss impairs prostate cancer cell proliferation and tumor formation. Loss of OGDHL reduces nucleotide synthesis, induces accumulation of the DNA damage response marker γH2AX, and alters androgen receptor inhibition–induced plasticity. Our data suggest that OGDHL has minimal impact on TCA cycle activity and that mitochondrial localization is not required for its regulation of nucleotide metabolism. Finally, we demonstrate that OGDHL expression is tightly correlated with neuroendocrine (NE) differentiation in clinical prostate cancer and that knockdown of OGDHL impairs the growth of cell line models of NE prostate cancer. These findings underscore the importance of investigating poorly characterized metabolic genes as potential regulators of distinct molecular subtypes of aggressive cancer. Implications: OGDHL emerged as an unexpected metabolic dependency associated with lineage plasticity and NE differentiation, implicating poorly studied metabolic enzymes as potential targets for treatment-resistant prostate cancer.

17 June 2026
Verified
Other
Open access
MBMatthew J. Bernard
Matthew J. Bernard
AGAndrea Gallardo
Andrea Gallardo
ARAngel Ruiz
Angel Ruiz
JDJohnny A. Diaz
Johnny A. Diaz
NNNicholas M. Nunley
Nicholas M. Nunley
AGAndrew S. Goldstein
Andrew S. Goldstein
Supplementary Figure S7. Differential expression analysis of OGDHL across multiple studies

17 June 2026
Verified
Other
Open access
MBMatthew J. Bernard
Matthew J. Bernard
AGAndrea Gallardo
Andrea Gallardo
ARAngel Ruiz
Angel Ruiz
JDJohnny A. Diaz
Johnny A. Diaz
NNNicholas M. Nunley
Nicholas M. Nunley
AGAndrew S. Goldstein
Andrew S. Goldstein
Supplementary Figure S6. Mitochondrial localization of OGDHL is not-required to regulate lineage and nucleotide phenotypes

17 June 2026
Verified
Other
Open access
MBMatthew J. Bernard
Matthew J. Bernard
AGAndrea Gallardo
Andrea Gallardo
ARAngel Ruiz
Angel Ruiz
JDJohnny A. Diaz
Johnny A. Diaz
NNNicholas M. Nunley
Nicholas M. Nunley
AGAndrew S. Goldstein
Andrew S. Goldstein
As cancer cells evade therapeutic pressure and adopt alternate lineage identities not commonly observed in the tissue of origin, they likely adopt alternative metabolic programs to support their evolving demands. Targeting these alternative metabolic programs in distinct molecular subtypes of aggressive prostate cancer may lead to new therapeutic approaches to combat treatment resistance. We identify the poorly studied metabolic enzyme oxoglutarate dehydrogenase-like (OGDHL), named for its structural similarity to the tricarboxylic acid (TCA) cycle enzyme oxoglutarate dehydrogenase, as an unexpected regulator of tumor growth, treatment-induced lineage plasticity, and DNA damage in prostate cancer. Although OGDHL has been described as a tumor suppressor in various cancers, we find that its loss impairs prostate cancer cell proliferation and tumor formation. Loss of OGDHL reduces nucleotide synthesis, induces accumulation of the DNA damage response marker γH2AX, and alters androgen receptor inhibition–induced plasticity. Our data suggest that OGDHL has minimal impact on TCA cycle activity and that mitochondrial localization is not required for its regulation of nucleotide metabolism. Finally, we demonstrate that OGDHL expression is tightly correlated with neuroendocrine (NE) differentiation in clinical prostate cancer and that knockdown of OGDHL impairs the growth of cell line models of NE prostate cancer. These findings underscore the importance of investigating poorly characterized metabolic genes as potential regulators of distinct molecular subtypes of aggressive cancer.Implications:OGDHL emerged as an unexpected metabolic dependency associated with lineage plasticity and NE differentiation, implicating poorly studied metabolic enzymes as potential targets for treatment-resistant prostate cancer.

17 June 2026
Verified
Other
Open access
MBMatthew J. Bernard
Matthew J. Bernard
AGAndrea Gallardo
Andrea Gallardo
ARAngel Ruiz
Angel Ruiz
JDJohnny A. Diaz
Johnny A. Diaz
NNNicholas M. Nunley
Nicholas M. Nunley
AGAndrew S. Goldstein
Andrew S. Goldstein
Supplementary Figure S1. Validation of Altered OGDHL Expression and reduction in growth in vitro and in vivo